论文部分内容阅读
肺结核(tuberculosis,TB)是由结核分枝杆菌(mycobacterium tuberculosis,M.tuberculosis)感染引起的,是发展中国家的重大人类疾病之一。人类免疫缺陷病毒(human immunodeficiency virus,HIV)和结核病的双重感染,以及多药耐药(multidrug-resistant,MDR)和广药耐药(extensively drug-resistant,XDR)结核分枝杆菌的出现使得抗结核的形势非常严峻,开发新型抗结核药物已经刻不容缓。鉴于形势如此迫切,研究人员开发了许多具有显著抗结核活性的化合物,其中有一些已经进入临床研究。本文对几类新型抗结核化合物的化学结构、构效关系、抗结核活性以及部分毒理性质进行了综述。
Tuberculosis (TB) is caused by Mycobacterium tuberculosis (M. tuberculosis) infection and is one of the major human diseases in developing countries. The dual infection of human immunodeficiency virus (HIV) and tuberculosis, along with the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Mycobacterium tuberculosis The situation of tuberculosis is very serious. It is urgent to develop new anti-tuberculosis drugs. Given the urgency of the situation, researchers have developed many compounds with significant anti-TB activity, some of which are already in clinical trials. In this paper, the chemical structure, structure-activity relationship, anti-TB activity and some toxicological properties of several new anti-TB compounds are reviewed.